Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas

Zhaoxia Li; Wei Guo; Ou Bai

doi:10.3389/fonc.2023.1301437

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas

Front Oncol. 2023 Dec 22:13:1301437. doi: 10.3389/fonc.2023.1301437. eCollection 2023.

Authors

Zhaoxia Li¹, Wei Guo¹, Ou Bai¹

Affiliation

¹ Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China.

Abstract

At present, the treatment of lymphoma has entered the era of precision medicine, and CD30, as a transmembrane protein, has become an important marker to help the diagnosis and formulation of treatment plans for lymphomas. This protein is widely expressed in various types of lymphomas and can play a role through nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and other pathways, and ultimately lead to the up-regulation of CD30 expression to give tumor cells a survival advantage. Brentuximab vedotin (BV), as an antibody-drug conjugate (ADC) targeting CD30, is one of the first new drugs to significantly improve survival in patients with CD30+lymphomas. However, the biological function of CD30 has not been fully elucidated. Therefore, this review highlights the CD30-mediated tumor-promoting mechanisms and the molecular factors that regulate CD30 expression. We hope that a better understanding of CD30 biology will provide new insights into clinical treatment and improve the survival and quality of life of lymphoma patients.

Keywords: BV; CD30; lymphomas; mechanism of action; targeted therapy.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Science and Technology Agency of Jilin province (20220402064GH).